These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3123614)

  • 1. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program.
    Jacobs J; Keyserling JA; Britton M; Morgan GJ; Wilkenfeld J; Hutchings HC
    J Clin Epidemiol; 1988; 41(3):215-23. PubMed ID: 3123614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medi-Cal") in 1995.
    Menzin J; Lang K; Friedman M; Neumann P; Cummings JL
    Am J Geriatr Psychiatry; 1999; 7(4):300-8. PubMed ID: 10521162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the Association Between Oral Glucocorticoids and Risk of Preterm Birth by Data Source: Reconciling the Results.
    Palmsten K; Bandoli G; Vazquez-Benitez G; Chambers CD
    Arthritis Care Res (Hoboken); 2022 Aug; 74(8):1332-1341. PubMed ID: 35089649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and utilization impacts of oral antihistamines in the California Medi-Cal program.
    Hay JW; Leahy M
    Value Health; 2005; 8(4):506-16. PubMed ID: 16091028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacy-enforced outpatient drug treatment protocols: a case study of Medi-Cal restrictions for cefaclor.
    McCombs JS; Nichol MB
    Ann Pharmacother; 1993 Feb; 27(2):155-61. PubMed ID: 8439688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector.
    Olivier N; Lubbe M; Joubert R; Naudé A; Burger J
    Value Health Reg Issues; 2018 Sep; 16():99-105. PubMed ID: 30227362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inequality of access to surgical specialty health care: why children with government-funded insurance have less access than those with private insurance in Southern California.
    Wang EC; Choe MC; Meara JG; Koempel JA
    Pediatrics; 2004 Nov; 114(5):e584-90. PubMed ID: 15520090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to urologic care for children in California: Medicaid versus private insurance.
    Hwang AH; Hwang MM; Xie HW; Hardy BE; Skaggs DL
    Urology; 2005 Jul; 66(1):170-3. PubMed ID: 15993479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to orthopedic care for children with medicaid versus private insurance in California.
    Skaggs DL; Clemens SM; Vitale MG; Femino JD; Kay RM
    Pediatrics; 2001 Jun; 107(6):1405-8. PubMed ID: 11389265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Children in foster care in California: an examination of Medicaid reimbursed health services utilization.
    Halfon N; Berkowitz G; Klee L
    Pediatrics; 1992 Jun; 89(6 Pt 2):1230-7. PubMed ID: 1594381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 1991 Jul; 33(848):65-70. PubMed ID: 1676134
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of disease-modifying antirheumatic drugs (DMARDs) in the therapy of rheumatoid arthritis].
    Cervini C; Salaffi F; Peroni M
    Clin Ter; 1993 Jan; 142(1):3-18. PubMed ID: 8472508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In California, Medi-Cal managed care is superior to Medi-Cal fee-for-service.
    Bruno R; Gilbert BP
    Manag Care Q; 1998; 6(4):7-14. PubMed ID: 10185780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Information needs for medication coverage decisions in a state Medicaid program.
    Croghan TW; Johnstone BM; Buesching DP; Kessler RC
    Med Care; 1999 Apr; 37(4 Suppl Lilly):AS24-31. PubMed ID: 10217390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leflunomide for rheumatoid arthritis.
    Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006-2009.
    Cifaldi M; Renaud J; Ganguli A; Halpern MT
    Curr Med Res Opin; 2016 Dec; 32(12):2029-2037. PubMed ID: 27551731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
    Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Runaway Costs in Medi-Cal-a myth.
    Heckman JR; Jones MW
    West J Med; 1980 Jun; 132(6):562-6. PubMed ID: 6996335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.